Amylyx Pharmaceuticals Files 8-K
Ticker: AMLX · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1658551
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Amylyx filed an 8-K, something happened, details to follow.
AI Summary
Amylyx Pharmaceuticals, Inc. filed an 8-K on October 17, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or new agreements.
Why It Matters
This 8-K filing indicates a material event has occurred for Amylyx Pharmaceuticals, requiring disclosure to investors, though the specific details are not yet provided in this initial report.
Risk Assessment
Risk Level: medium — The filing of an 8-K signals a significant event, but the lack of immediate detail creates uncertainty about its impact.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- October 17, 2024 (date) — Date of earliest event reported
- 43 Thorndike St. (location) — Principal executive offices address
- Cambridge, MA (location) — Principal executive offices city and state
- 02141 (location) — Principal executive offices zip code
- (617) 682-0917 (phone_number) — Registrant's telephone number
FAQ
What specific event triggered this 8-K filing for Amylyx Pharmaceuticals?
The filing states 'Other Events' as the item information, but does not specify the exact event in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 17, 2024.
What is the principal executive office address for Amylyx Pharmaceuticals?
The principal executive offices are located at 43 Thorndike St., Cambridge, MA 02141.
What is the SEC file number for Amylyx Pharmaceuticals?
The SEC file number for Amylyx Pharmaceuticals is 001-41199.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This current report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,312 words · 5 min read · ~4 pages · Grade level 10.1 · Accepted 2024-10-17 09:12:58
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
Filing Documents
- d858945d8k.htm (8-K) — 43KB
- 0001193125-24-238572.txt ( ) — 161KB
- amlx-20241017.xsd (EX-101.SCH) — 3KB
- amlx-20241017_lab.xml (EX-101.LAB) — 17KB
- amlx-20241017_pre.xml (EX-101.PRE) — 11KB
- d858945d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: October 17, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer